Ligand Pharma (LGND) PT Raised to $150 at Oppenheimer
Tweet Send to a Friend
Oppenheimer analyst Trevor Allred raised the price target on Ligand Pharma (NASDAQ: LGND) to $150.00 (from $135.00) while maintaining an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
